Biologic therapies are widely used in inflammatory diseases, and they are associated to an increased infection risk, especially to granulomatous and intracellular infections such as Legionella. A review of the literature revealed 105 cases of Legionella pneumonia in patients taking biologic therapies. Sixty-four patients (65.3%) were treated with infliximab, 23 (23.5%) with adalimumab, 5 (5%) with etanercept and 3 (3%) with rituximab. Seventy-one per cent of the patients were treated for rheumatologic diseases and 16% for inflammatory bowel diseases. The majority of the patients received one or more concomitant immunosuppressive drugs, especially steroids (43%). Overall mortality was 19%. Legionella pneumonia might complicate therapy with biologic therapies, especially in patients being treated with infliximab or adalimumab given concomitantly with other immunosuppressive medications during their first 6 months of treatment. Physicians should be aware of this potentially severe association. Early recognition and treatment would likely result in reduced morbidity and mortality.
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INTRODUCTION
Biologic agents approved for clinical use include tumour necrosis factor alpha inhibitors (anti-TNFα) such as etanercept, infliximab, adalimumab, golimumab, and certolizumab pegol; the interleukin (IL)-1 receptor antagonist, anakinra; the T-cell costimulation inhibitor, abatacept; the humanised monoclonal antibody targeting the interleukin-6 receptor, tocilizumab; a monoclonal antibody against B-cell-specific CD20 antigen, rituxamab; a fully human monoclonal antibody that binds to B-lymphocyte stimulator, belimumab; and a monoclonal antibody which binds to α 4 β 1 integrin, a protein on the surface of lymphocytes, blocking their union to the endothelial receptor, natalizumab.
These biologic therapies are widely used in patients treated for inflammatory diseases.
Although the overall infection risk remains a subject of open debate, some studies have reported an increased risk of granulomatous and intracellular infections, such as tuberculosis, listeriosis and legionellosis 1, 2 . The United States Food and Drug Administration (FDA) has added risk of these infections as a Boxed Warning for the entire class of TNFα inhibitors.
TNFα is synthesized by macrophages in response to proinflammatory stimuli and acts as a central mediator of inflammation and immune regulation. However, TNFα is also important in host defence and plays a role in the immune-mediated response to infection because it induces the release of cytokines and local chemokines, leading to attraction and stimulation of phagocytes, increased T-cell adhesion, and enhanced antigen presentation with recruitment and proliferation of T and B cells 3, 4 . Furthermore, murine studies found a protective effect of TNF in experimental Legionella pneumophila infections 5, 6 . Its antigenic components, especially, lipopolysaccharide, are a strong stimulus to produce TNFα, which induces a cell-M A N U S C R I P T
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4 mediated immune response. Rats infected with L. pneumophila and treated with antiTNFα antagonists showed persistent pneumonitis with a higher bacterial load, more infected macrophages and less recruitment of peripheral blood monocytes to the lung compared to control rats 5, 6 .
Given the theoretic increased risk of legionellosis in patients receiving biologic therapies, we aimed to analyse the association between Legionella pneumonia among these patients. Our purpose was to characterise the clinical presentation, duration of biologic treatment at onset of infection, the use of concomitant immunosuppressive medication and outcomes of the Legionella infection cases in patients treated with biologics.
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MATERIAL AND METHODS
We searched the publicly available Adverse Event Reporting System (AERS) database of the PubMed search using the terms "legionella" and "biologics" or "tumour necrosis factor
antagonists" and included all cases reports in our analysis 1, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] .
For our analysis we included the Medical Dictionary for Regulatory Activities (MedDRA) 
RESULTS
We found 105 cases of Legionella infection, 68 of which were from FDA AERS. Other data were from national registries (19 cases) and isolated case reports (18 cases). The main characteristics of the reported cases are described in table 1. Speciation was not denoted in the FDA AERS reports. In all other cases in which speciation were performed, the species was L. pneumophila (30 cases).
Sixty-one per cent of the patients were males. The median age was 52 years (range 25 to 87 years). North America and Europe accounted for the bulk of reported cases. France was the country which reported the most episodes (27) , followed by United States (10), Spain (10),
Italy (10), the United Kingdom (8), Canada (7) and Germany (6).
Infliximab was the biologic most frequently related to Legionella infection (65.3% of reported cases), followed by adalimumab (23.5%), etanercept (5%), rituximab (3%), abatacept (1%) and natalizumab (1%). One patient received a combination of adalimumab and infliximab. Denominator data is not available so the proportion of patients receiving any specific biologic agent was not calculable. The majority of the patients received one or more concomitant immunosuppressive drugs, especially corticosteroids (43%), methotrexate Three patients were given inappropriate empirical antibiotic treatment in a total of only 8 patients in whom the initial antibiotic treatment was recorded -two of these three patients died 9, 13 .
Seventeen deaths were reported from 92 patients in whom outcome was recorded (19%). At least 9 survivors required intensive care unit management. 27 . An EB05 value of 8.7 was discovered, implying that the drugevent pair has been reported 8.7 times as frequently as would be expected if reports involving the drug and reports of the event were independent (that is, no association). In contrast, the EB05 for tuberculosis was 20.9 27 .
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Infliximab, which was first approved by the FDA in 2000, was the most commonly reported two-thirds could be explained by selective switching of patients who were at increased risk of infection 28 .
The fact that most of the analysed cases received other immunosuppressive therapies concomitantly is remarkable. There are certainly other reports that describe legionellosis in immunosupressed patients who have not received biologic therapies [29] [30] [31] [32] . Interestingly, systemic corticosteroids were extensively used among these patients in similar proportions to that in our study, suggesting that it might have played a role in the infection. Furthermore, these studies described a high case fatality rate, ranging from 14.3% in solid organ transplant recipients to 31% in cancer patients, in concordance with our study which reported a mortality of 19%. These rates differ from the ones reported from community-acquired cases in non immunosupressed patients which are between 2.5-6% 33, 34 .
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It would have been interesting to know how many cases received inappropriate empirical antibiotic treatment and how long it took to get the diagnosis -and if delays were associated with increased mortality. In our analysis, only 8 cases had this kind of information and 3 of these patients received inappropriate empirical antibiotic therapy, resulting in 2 deaths.
Although we do not have enough data to draw conclusions, one of the factors that could contribute our high mortality rate is a delay in diagnosis and consequently in adequate Definitive diagnosis is based on cultures of the microorganism from respiratory secretions or pleural fluid. The utility of serology is limited, except for retrospectively proving that an infection has occurred.
Our study has some limitations. First of all, the voluntary nature of physician reports to the FDA AERS may underestimate the real incidence of legionellosis. Secondly, some reports may have been registered in the FDA AERS database and also published or included in national registries, therefore resulting in duplicate information. For example, France was the country that reported most cases, almost 3-fold comparing to United States, Spain and Italy, which were the next countries in order of frequency. It is possible this incidence could be overestimated if some of the cases were reported twice. Furthermore, some information about
case reports is lacking and therefore there is limited statistical power and denominator data is not available so the proportion of patients receiving any specific biologic agent was not calculable.
Finally we conclude that as biologic therapies are increasingly used to treat some inflammatory diseases we should be aware that they may increase susceptibility to cause certain infections such as Legionella pneumonia. The highest risk appears to be in patients 
